Treatment of Advanced/Metastatic Liposarcoma with Clinically Resectable Lung Metastases
This protocol addresses the management of liposarcoma that has progressed to an advanced or metastatic stage, specifically where lung metastases are present but considered clinically resectable, and there is no evidence of extrapulmonary disease.
Clinical Scenario
Advanced or metastatic liposarcoma with resectable lung metastases (e.g. metachronous pulmonary lesions with a disease-free interval of at least one year) and no extrapulmonary spread, where complete excision of all lesions is considered feasible.
Treatment Approach (partial overview)
Surgical resection is the standard approach for eligible patients. In selected cases, a minimally invasive technique may be appropriate. Systemic therapy may also play a role alongside surgery, with specific timing considerations — particularly when certain prognostic factors are present.
The complete regimen, sequencing, and eligibility criteria are available in the full structured protocol.
References
DOI: 10.1016/j.annonc.2021.07.006
- Advanced/metastatic, clinically resectable STS.
- Standard treatment of metachronous (disease-free interval 1 year), resectable lung metastases without extrapulmonary disease is surgery, if complete excision of all lesions is feasible [IV, B].
- A minimally invasive thoracoscopic approach can be used in selected cases.
- ChT may be added to surgery as an option, taking into account the prognostic factors (a short previous recurrence-free interval and a high number of lesions are adverse factors, encouraging the addition of ChT), although there is a lack of formal evidence that this improves outcome [IV, B].
- ChT is preferably given before surgery to assess tumour response and modulate treatment.
View source ↗